Gerke Ingrid, Kaup Franz-Josef, Neumann Stephan
Institute of Veterinary Medicine, Georg August University of Goettingen, Burckhardtweg 2, (Gerke, Neumann); Pathology Unit, German Primate Center, Leibniz-Institute for Primate Research, Kellnerweg 4, 37077 Goettingen, Germany (Kaup).
Can J Vet Res. 2018 Apr;82(2):115-123.
Studies in humans have shown that the ubiquitin-proteasome pathway and the insulin-like growth factor axis are involved in carcinogenesis, thus, components of these systems might be useful as prognostic markers and constitute potential therapeutic targets. In veterinary medicine, only a few studies exist on this topic. Here, serum concentrations of 26S proteasome (26SP) and insulin-like growth factor-1 (IGF-1) were measured by canine enzyme-linked immunosorbent assay (ELISA) in 43 dogs suffering from malignant tumors and 21 clinically normal dogs (control group). Relationships with tumor size, survival time, body condition score (BCS), and tumor entity were assessed. The median 26SP concentration in the tumor group was non-significantly higher than in the control group. However, dogs with mammary carcinomas displayed significantly increased 26SP levels compared to the control group and dogs with tumor size less than 5 cm showed significantly increased 26SP concentrations compared to dogs with larger tumors and control dogs. 26SP concentrations were not correlated to survival time or BCS. No significant difference in IGF-1 levels was found between the tumor group and the control group; however, IGF-1 concentrations displayed a larger range of values in the tumor group. Dogs with tumors greater than 5 cm showed significantly higher IGF-1 levels than dogs with smaller tumors. The IGF-1 concentrations were positively correlated to survival time, but no correlation with BCS was found. Consequently, serum 26SP concentrations seem to be increased in some dogs suffering from malignant tumors, especially in dogs with mammary carcinoma and smaller tumors. Increased serum IGF-1 concentrations could be an indication of large tumors and a poor prognosis.
人体研究表明，泛素 - 蛋白酶体途径和胰岛素样生长因子轴参与致癌过程，因此，这些系统的组成部分可能作为预后标志物有用，并构成潜在的治疗靶点。在兽医学中，关于这个主题的研究很少。在这里，通过犬酶联免疫吸附测定（ELISA）测量了43只患有恶性肿瘤的犬和21只临床正常犬（对照组）的血清26S蛋白酶体（26SP）和胰岛素样生长因子 -1（IGF-1）浓度。评估了与肿瘤大小、生存时间、身体状况评分（BCS）和肿瘤类型的关系。肿瘤组中26SP浓度的中位数略高于对照组，但无统计学意义。然而，与对照组相比，患有乳腺癌的犬26SP水平显著升高，与肿瘤较大的犬和对照犬相比，肿瘤大小小于5 cm的犬26SP浓度显著升高。26SP浓度与生存时间或BCS无关。肿瘤组和对照组之间的IGF-1水平没有显著差异；然而，肿瘤组中IGF-1浓度的取值范围更大。肿瘤大于5 cm的犬的IGF-1水平显著高于肿瘤较小的犬。IGF-1浓度与生存时间呈正相关，但与BCS无关。因此，一些患有恶性肿瘤的犬，特别是患有乳腺癌和较小肿瘤的犬，血清26SP浓度似乎会升高。血清IGF-1浓度升高可能表明肿瘤较大且预后不良。
